- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00032591
The Home INR Study (THINRS)
CSP #481 - The Home INR Study (THINRS)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Intervention: Weekly patient self-testing (PST) of prothrombin time by international normalized ratio (PT INR) versus conventional monthly high quality anticoagulation management (HQACM) from an anticoagulation clinic with a minimum two years follow-up.
Primary Hypothesis: Compared to conventional monitoring in the clinic, PST of anticoagulation intensity will decrease the number of events of thromboembolism (strokes), bleeding, and all cause deaths and improve the quality of anticoagulation.
Second Hypothesis: PST and conventional monitoring will be comparable in terms of health care utilization and cost.
Primary Outcomes: Event rates (thromboembolism or bleeding episodes), time to first event, time within therapeutic range for anticoagulation intensity, and total health care cost (including price of PST monitors) and utilization.
Study Abstract: Since home monitors of prothrombin time (PT) may potentially improve the safety, quality, and convenience of chronic anticoagulation management, it is likely that there will be demands from providers, patients, and manufacturers to make home monitors available to VA patients. The rationale for PST is that it would permit more intense monitoring and increased patient participation in his/her own care, resulting in increased precision in anticoagulation control and thus fewer events.
Original plan was for a study at 32 sites with a total sample size of about 3,200 patients and a length of three years (one for recruitment and two years of follow-up). Final status was 28 sites that randomized 2922 patients in 2.75 years of recruitment with a minimum of two years of follow-up.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- VA Medical Center, Birmingham
-
-
California
-
Fresno, California, Estados Unidos, 93703
- VA Central California Health Care System, Fresno
-
Loma Linda, California, Estados Unidos, 92357
- VA Medical Center, Loma Linda
-
Palo Alto, California, Estados Unidos, 94304-1290
- VA Palo Alto Health Care System
-
West Los Angeles, California, Estados Unidos, 90073
- VA Greater Los Angeles Healthcare System, West LA
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80220
- VA Eastern Colorado Health Care System, Denver
-
-
Connecticut
-
West Haven, Connecticut, Estados Unidos, 06516
- VA Connecticut Health Care System (West Haven)
-
-
Illinois
-
Hines, Illinois, Estados Unidos, 60141-5000
- Edward Hines, Jr. VA Hospital
-
North Chicago, Illinois, Estados Unidos, 60064
- VA Medical Center, North Chicago
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52246-2208
- VA Medical Center, Iowa City
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- VA Maryland Health Care System, Baltimore
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- John D. Dingell VA Medical Center, Detroit
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55417
- VA Medical Center, Minneapolis
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64128
- VA Medical Center, Kansas City MO
-
-
Nevada
-
North Las Vegas, Nevada, Estados Unidos, 89036
- Las Vegas
-
Reno, Nevada, Estados Unidos, 89502
- VA Sierra Nevada Health Care System
-
-
New York
-
Bronx, New York, Estados Unidos, 10468
- VA Medical Center, Bronx
-
Buffalo, New York, Estados Unidos, 14215
- VA Western New York Healthcare System at Buffalo
-
Syracuse, New York, Estados Unidos, 13210
- VA Medical Center, Syracuse
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Durham VA Medical Center HSR&D COE
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- VA Medical Center, Cleveland
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- VA Medical Center, Oklahoma City
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15240
- VA Pittsburgh Health Care System
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02908
- VA Medical Center, Providence
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75216
- VA North Texas Health Care System, Dallas
-
San Antonio, Texas, Estados Unidos, 78229
- VA South Texas Health Care System, San Antonio
-
-
Virginia
-
Salem, Virginia, Estados Unidos, 24153
- VA Medical Center, Salem VA
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53705
- Wlliam S. Middleton Memorial Veterans Hospital, Madison
-
-
-
-
-
San Juan, Puerto Rico, 00921
- VA Medical Center, San Juan
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
To be enrolled in this study, patients must:
- have AF and/or a MHV;
- be scheduled to receive warfarin indefinitely (operationally defined as 2 years);
- be using warfarin according to the criteria described in the Coumadin package insert (no off-label uses);
- be expected to survive for the duration of the study;
- not be suffering from intracranial bleeding (intracranial hemorrhage, subarachnoid hemorrhage, hemorrhagic stroke) or any other contraindication described in the Coumadin package insert;
- be willing to perform PST;
- be willing to be randomized;
- possess adequate cognitive and language skills to follow the protocol and all related instructions;
- be willing to participate for the full duration of the study;
- sign the informed consent form; and
- not be enrolled in another randomized clinical trial that involves a drug or device intervention.
Exclusion Criteria:
Patients are excluded in this study if:
- subject has had intracranial hemorrhage, subarachnoid hemorrhage, hemorrhagic stroke, or any other absolute/major contraindication described in the warfarin package insert within the last month
- subject enrolled in another randomized clinical trial that involves a drug or device intervention
- subject is not able to follow the protocol and all related instructions, and does not have a caregiver with these skills
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Arm 1
Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
|
|
Otro: Arm 2
High quality anticoagulation management (HQACM) with conventional monthly testing
|
HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time to First Event (Death, Stroke, Major Bleed)
Periodo de tiempo: Time to event
|
Time to first event (death, stroke, major bleed) The primary outcome was time to first event, and we used the Kaplan-Meier method to compare survival curves and the results using the log-rank test. The number of patients with a primary outcome is what was reported in the NEJM paper. Below is the unpublished cumulative incidence information. |
Time to event
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time in Therapeutic Range Over Full Length of Follow-up (0 to 100 Percent)
Periodo de tiempo: Full length of follow-up; average of 3 years
|
Time in target range (TTR) based on Prothrombin Time standardized to the International Normalized Ratio
|
Full length of follow-up; average of 3 years
|
DASS at 2 Years of Follow-up
Periodo de tiempo: At two years of follow-up
|
Satisfaction with care was quantified using the Duke Anticoagulation Satisfaction Scale (DASS).
Scores range from 25 to 225, with lower scores indicating higher satisfaction.
|
At two years of follow-up
|
Cumulative Gain in Health Utilities at 2 Year
Periodo de tiempo: After 2 years of follow-up for each subject
|
Scores range from -0.36 to 1.00 per year, with a negative score indicating a state worse than being dead and a score of 1.00 indicating perfect health.
Since the time frame is 2 years, the range is -0.72 to 2.00.
|
After 2 years of follow-up for each subject
|
Health Care Costs at 2 Year
Periodo de tiempo: After 2 years of follow-up for each subject
|
After 2 years of follow-up for each subject
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: David B. Matchar, MD, Durham VA Medical Center HSR&D COE
Publicaciones y enlaces útiles
Publicaciones Generales
- Dolor RJ, Ruybalid RL, Uyeda L, Edson RG, Phibbs C, Vertrees JE, Shih MC, Jacobson AK, Matchar DB; THINRS Site Investigators. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis. 2010 Oct;30(3):263-75. doi: 10.1007/s11239-010-0499-8.
- Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010 Oct 21;363(17):1608-20. doi: 10.1056/NEJMoa1002617. Erratum In: N Engl J Med. 2011 Jan 6;364(1):93.
- Matchar DB, Jacobson AK, Edson RG, Lavori PW, Ansell JE, Ezekowitz MD, Rickles F, Fiore L, Boardman K, Phibbs C, Fihn SD, Vertrees JE, Dolor R. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS). J Thromb Thrombolysis. 2005 Jun;19(3):163-72. doi: 10.1007/s11239-005-1452-0.
- Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, Matchar DB; writing for the THINRS Executive Committee and Site Investigators. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). J Gen Intern Med. 2016 Sep;31(9):1061-7. doi: 10.1007/s11606-016-3700-8. Epub 2016 May 27.
- Matchar DB, Love SR, Jacobson AK, Edson R, Uyeda L, Phibbs CS, Dolor RJ. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. 2015 Jul;40(1):17-25. doi: 10.1007/s11239-014-1128-8.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 481
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrilación auricular
-
The Second Affiliated Hospital of Chongqing Medical...TerminadoFibrilación auricular | Hipertensión,Esencial | Dilatación atrial izquierdaPorcelana
-
Region SkaneReclutamientoFibrilación auricular | Dilatación atrial izquierdaSuecia
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)ReclutamientoEnfermedades Renales | Hipertensión | Obesidad Pediátrica | Proteinuria | Albuminuria | Lesión renal | Trastornos de la presión arterial | Disfunción autonómica | Enfermedad renal pediátrica | Disfunción Ventricular Izquierda | Hipertrofia del ventrículo izquierdo | Disfunción renal | Desequilibrio autonómico | Disfunción... y otras condicionesEstados Unidos